Science & academia

This archive covers milestones and breakthroughs from the scientific and academic world — researchers, universities, and institutions whose work advances human knowledge. Stories here highlight discoveries, studies, and scholarly efforts that point toward a better future.

Blood cells under microscope, for article on smart insulin, for article on lab-grown blood cells

First human patients receive transfusions of lab-grown blood cells

By / / Good News For Humankind

Lab-grown blood cells have reached a genuine turning point: manufactured red blood cells grown from stem cells have been safely transfused into human patients for the first time. What makes these cells special is their freshness — unlike donated blood, every lab-grown cell is the same age, meaning they should last closer to the full 120-day lifespan and reduce repeat transfusions. Early participants completed the process with no adverse effects. For millions worldwide living with blood disorders or rare blood types, this science crossing into human trials is the kind of progress that quietly changes everything.

Cancer cells, for article on radioactive implant pancreatic cancer

Radioactive implant wipes tumors in unprecedented pre-clinical success

By / / Good News For Humankind

Pancreatic cancer is one of the hardest diseases medicine has ever faced, and a new implant from Duke University is producing results that researchers say have no match in the existing scientific record. The device injects a radioactive gel directly into tumors, trapping iodine-131 so it radiates from the inside out before safely dissolving into harmless amino acids. Combined with chemotherapy, it eliminated tumors in the majority of mouse models tested. Human trials remain ahead, but for a disease where survival gains have been painfully slow, this early signal is genuinely remarkable.

Measuring Psilocybin Magic Mushroom Micro Doses in Laboratory for A Scientific Experiment, for article on psilocybin therapy

The world’s first Phase 3 psilocybin clinical trial is about to commence

By / / Good News For Humankind

Psilocybin therapy is making history: Compass Pathways will launch the world’s first Phase 3 trial for treatment-resistant depression by the end of 2022, enrolling nearly 1,000 participants across two pivotal studies. This is the threshold every promising drug must cross to become an approved medicine, and no psychedelic compound has crossed it before. For the roughly 100 million people worldwide whose depression doesn’t respond to standard treatments, the stakes are real — current options are few, often invasive, and inconsistently helpful. A single guided dose, if the evidence holds, could reshape what care looks like. Beyond depression, this moment signals that a long-stigmatized class of medicines is finally being tested with the rigor patients deserve.

Newborn baby being held, for article on spina bifida treatment

World-first stem cell therapy trial treats spina bifida before birth

By / / Good News For Humankind

Spina bifida causes nerve damage that accumulates in the womb, and until now, medicine could only respond after that damage was done. A clinical trial at UC Davis Health is changing that window, applying a stem cell patch directly to a fetus’s spine during pregnancy to support repair before birth. The first baby treated was expected to arrive with leg paralysis — instead, she was kicking and wiggling her toes. If results hold across all 35 enrolled patients, this could establish a genuinely new standard of care for a condition that currently offers families very little hope.

China compressed air energy storage, for article on compressed air energy storage

China turns on the world’s largest and most efficient compressed air energy storage plant

By / / Good News For Humankind

Clean energy storage just took a major leap forward, and it happened without a single fossil fuel involved. China’s new compressed air facility in Zhangjiakou runs entirely on thermodynamic processes, storing up to 400 MWh and operating at 70.4% efficiency — well above the 40–52% typical of existing systems. That’s enough to supply more than 132 GWh to the local grid annually, while avoiding roughly 109,000 tons of CO₂ each year. Proving that utility-scale, non-lithium storage can work commercially gives the global clean energy transition a powerful new tool to build on.

Injecting vaccine, for article on India HPV vaccine

Indian company develops country’s first HPV vaccine

By / / Good News For Humankind

CERVAVAC, India’s first homegrown cervical cancer vaccine, is priced at just $2.50 to $5.00 per dose — a fraction of what HPV vaccines have cost in wealthy countries for nearly two decades. Developed by the Serum Institute of India, it protects against the HPV strains responsible for the majority of cervical cancers worldwide, and the company aims to produce around 200 million doses in its first two years. Cervical cancer is almost entirely preventable, yet it still kills hundreds of thousands of women each year, mostly in lower-income countries where vaccines have been priced out of reach. An affordable, locally made option doesn’t just change the math for India — it points toward a future where health tools belong to the people who need them most.

Female scientist pipetting colored chemicals into a tube, for article on CAR T-cell therapy

Scientists hail autoimmune disease therapy breakthrough

By / / Good News For Humankind

Lupus remission in all five patients — that’s the striking result from a small German trial using CAR T-cell therapy, a treatment originally developed for blood cancers. Doctors collected each patient’s own T-cells, reprogrammed them to clear out the malfunctioning B cells driving the disease, and reinfused them. Months later, the patients’ immune systems had essentially rebooted: new B cells grew back, but they no longer attacked the body. None have needed lupus medication since. The lead researcher believes the same approach could help people with rheumatoid arthritis, multiple sclerosis, and other autoimmune conditions — opening a hopeful new chapter for millions worldwide who have long managed their illness without ever truly being free of it.